title: Non-gastric extra-nodal marginal zone lymphomas--a single centre experience on 76 patients.
abstract: In the present study, we assessed the clinical and pathological data of 76 patients with the diagnosis of non-gastric extranodal marginal zone B-cell lymphoma. The most commonly affected sites were salivary glands, skin, ocular adnexa, lung, intestine and Waldeyer's ring. Ann Arbor stage I disease was present in 39 patients (51%), stage II in 10 (13%) and stage IV in 27 (36%). In 17 cases (21%), the lymphoma presented at multiple mucosal sites. Lymph node and bone marrow involvement were present in 21% and 16%, respectively. Most cases were in the low or low-intermediate risk group. Treatment was heterogeneous and included chlorambucil in 59% either alone or in combination with other agents. Complete and partial remission was achieved in 79% and 7%, respectively, with an overall response rate of 86%. The 5- and 10-year overall survival and cause-specific survival rates were 94%, 82% and 95%, 91%, respectively. The 5- and 10-year progression free survival was 56% and 41%, respectively. The only feature associated with inferior outcome was disease localisation to the lung.
authors.affiliation: Department of Haematology, University of Crete, Medical School, University Hospital of Heraklion, Heraklion Crete, Greece.
authors.forename: Christina
authors.initials: C
authors.lastname: Kalpadakis
authors.forename: Gerassimos A
authors.initials: GA
authors.lastname: Pangalis
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Vassilakopoulos
authors.forename: Maria-Christina
authors.initials: MC
authors.lastname: Kyrtsonis
authors.forename: Marina P
authors.initials: MP
authors.lastname: Siakantaris
authors.forename: Flora N
authors.initials: FN
authors.lastname: Kontopidou
authors.forename: Penelope
authors.initials: P
authors.lastname: Korkolopoulou
authors.forename: Panagia
authors.initials: P
authors.lastname: Bobotsis
authors.forename: Sotirios
authors.initials: S
authors.lastname: Sahanas
authors.forename: Tatiana
authors.initials: T
authors.lastname: Tzenou
authors.forename: Dimitra
authors.initials: D
authors.lastname: Anagnostou
authors.forename: Evangelia
authors.initials: E
authors.lastname: Dimitriadou
authors.forename: Xanthi
authors.initials: X
authors.lastname: Yiakoumis
authors.forename: Evangelos
authors.initials: E
authors.lastname: Patsouris
authors.forename: Panagiota
authors.initials: P
authors.lastname: Roussou
authors.forename: Panayiotis
authors.initials: P
authors.lastname: Panayiotidis
authors.forename: Eleni
authors.initials: E
authors.lastname: Papadaki
authors.forename: Maria K
authors.initials: MK
authors.lastname: Angelopoulou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D002699:Chlorambucil